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The phagocytosis of apoptotic cells (ACs), or efferocytosis, by DCs is critical for self-tolerance and host defense. 
Although many efferocytosis-associated receptors have been described in vitro, the functionality of these recep-
tors in vivo has not been explored in depth. Using a spleen efferocytosis assay and targeted genetic deletion in 
mice, we identified a multiprotein complex — composed of the receptor tyrosine kinase AXL, LDL receptor– 
related protein–1 (LRP-1), and RAN-binding protein 9 (RANBP9) — that mediates DC efferocytosis and antigen 
cross-presentation. We found that AXL bound ACs, but required LRP-1 to trigger internalization, in murine 
CD8α+ DCs and human-derived DCs. AXL and LRP-1 did not interact directly, but relied on RANBP9, which 
bound both AXL and LRP-1, to form the complex. In a coculture model of antigen presentation, the AXL/
LRP-1/RANBP9 complex was used by DCs to cross-present AC-associated antigens to T cells. Furthermore, in 
a murine model of herpes simplex virus–1 infection, mice lacking DC-specific LRP-1, AXL, or RANBP9 had 
increased AC accumulation, defective viral antigen-specific CD8+ T cell activation, enhanced viral load, and 
decreased survival. The discovery of this multiprotein complex that mediates functionally important DC effero-
cytosis in vivo may have implications for future studies related to host defense and DC-based vaccines.
Introduction
Efferocytosis is the process by which apoptotic cells (ACs) are rec-
ognized and cleared by phagocytic cells (1, 2). The crucial role of 
this process is exemplified by the development of spontaneous 
autoimmunity secondary to breakdown of self-tolerance in mice 
lacking certain efferocytosis receptors or their bridging molecules 
(3–6). Whereas macrophages are highly efficient at AC uptake (7) 
and are usually the focus of efferocytosis studies, efferocytosis by 
DCs can mediate the presentation of AC-associated antigens on 
MHC class I to naive and memory CD8+ T cells in a process called 
cross-presentation. This process has been proposed to induce 
either antigenic tolerance (8) or T cell priming against infectious 
agents (9), depending on the specific context. Mostly in vitro stud-
ies have identified a number of distinct efferocytosis receptors that 
can be used by DCs (7, 10, 11), suggestive of possible redundancy 
or tissue- or context-specific usage. However, the identity and 
mechanisms of receptors utilized by DCs to perform functionally 
important efferocytosis and cross-presentation in vivo constitutes 
a major gap in this important area of research.
Previous reports showed that the efferocytosis receptors CD36, 
αvβ5, and αvβ3 are not involved in antigen cross-presentation by 
DCs (12, 13). Bone marrow–derived DCs (BMDCs) from the AXL/
TYRO3 double-KO mouse demonstrate defective efferocytosis 
in vitro (11), but the role of AXL/TYRO3 in DC efferocytosis in 
vivo and in cross-presentation is not known. An important study 
showed that T cell Ig domain and mucin domain 3 (TIM-3) par-
ticipates in AC uptake by DCs and cross-presents a model antigen 
OVA to OT-I transgenic T cells (10). However, the relative con-
tribution of TIM-3 in the context of other DC receptors and in 
functionally relevant cross-presentation is not known, especially 
because TIM-3 is also a negative regulator of T cell activation (14). 
Recently, scavenger receptor class F, member 1 (SCARF-1), was 
reported to be important for efferocytosis by DCs, and SCARF-1– 
deficient mice developed a lupus-like autoimmune disease (15). 
However, whether SCARF-1 plays a role in antigen cross-presen-
tation or is utilized by human DCs was not explored. Given the 
critical role of DC efferocytosis and cross-presentation in main-
taining tissue homeostasis, peripheral tolerance, and elicitation of 
antiviral immunity upon infection and vaccination, identification 
of the mechanisms and functionality of DC efferocytosis receptors 
in vivo is of paramount importance.
To address this critical gap in DC biology, we first used an 
in vivo spleen efferocytosis assay in which mice with absent or 
inhibited candidate DC efferocytosis receptors were injected with 
labeled ACs, followed by analysis of AC uptake by splenic DCs. 
Based on these initial findings, we carried out molecular-cellular 
studies and then gene-targeted mouse experiments to interrogate 
mechanism and function. This investigation led to the identi-
fication of a multiprotein efferocytosis complex that mediates 
DC efferocytosis in vivo. The proteins in the complex, AXL, LDL 
receptor–related protein–1 (LRP-1; also known as CD91), and 
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RAN-binding protein 9 (RANBP9), were unable to effect effero-
cytosis on their own, but rather functionally interacted to coor-
dinate AC binding and internalization. Most importantly, these 
molecules played a substantial, nonredundant role in the cross-
presentation of AC-associated antigens in vivo, including in clear-
ance of a viral infection. Human splenic and monocyte-derived 
DCs also used these molecules for efferocytosis. Knowledge of the 
presence and functionality of this multiprotein complex in DC 
efferocytosis may have implications for future studies related to 
host defense and DC-based vaccines.
Results
Splenic DCs utilize AXL, LRP-1, and TIM-3 for clearance of ACs in vivo 
and in vitro. As a first approach to interrogating DC efferocytosis 
in vivo, we injected PKH67-labeled ACs into mice and then quanti-
fied the uptake of those ACs by splenic DCs using flow cytometry 
(16). To help validate this assay, we took advantage of the fact that 
mature splenic DCs, which can be increased in mice by injection 
with the Toll-like receptor activator CpG-DOTAP, and CD8α– 
splenic DCs have low efferocytosis efficiency (7, 17). The assay suc-
cessfully identified DCs from CpG-treated mice and CD8α– DCs 
Figure 1
In vivo splenic DC efferocytosis assay. (A) Flow cytometric detection of cells that costained for PKH67 (square gate) in the splenocytes of mice 
injected with PKH67-labeled ACs. (B) Analysis and quantification (n = 3 per group) of the AC-gated region in A to determine the proportion of ACs 
that were internalized by splenic DCs (CD11c+) in C57BL/6J mice injected with vehicle control (Con) or the DC maturation stimulus CpG-DOTAP. 
Numbers represent the percentage of cells in the respective quadrants. (C) Flow cytometric analysis and quantification (n = 3 mice per group) of 
the distribution of internalized ACs between the CD8α+ and CD8α– subsets of CD11c+PKH67+-gated splenocytes. (D) Top: Confocal microscopy 
z section sequence (top-to-bottom at 2-μm intervals) of FACS-sorted CD11c+PKH67+ splenic DCs (representative of cells in the top-right quadrant 
of B), demonstrated the presence of ACs inside the DCs. Red, PE staining of splenic CD11c+ cells; green, PKH67-labeled ACs. Bottom: z section 
sequence of BMDCs (red) treated with 5 μg/ml cytochalasin D (CytoD) prior to addition of ACs (green) to demonstrate what a DC would look if 
there was AC binding, but not engulfment. Scale bars: 5 μm. (E) Comparison of in vivo splenic DC efferocytosis in mice injected with ACs labeled 
with PKH67 or Cypher-5E (n = 3 per group). *P < 0.05 vs. respective control.
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as poor efferocytes compared with DCs from untreated mice and 
CD8α+ DCs, respectively (Figure 1, A–C). Furthermore, FACS sort-
ing and confocal microscopic analysis of CD11c+PKH67+ spleno-
cytes revealed that more than 97% of these cells showed evidence 
of AC internalization. A representative image demonstrating inter-
nalization of ACs in these sorted cells (CD11c+ gate; Figure 1B) is 
shown in Figure 1D. As an example of what noninternalization of 
ACs would look like by confocal microscopy, BMDCs were treated 
with the actin polymerization inhibitor cytochalasin D prior to 
addition of ACs. The z section sequence in this case showed that 
ACs were present only at the cell surface (Figure 1D). To further 
demonstrate internalization, we showed that efferocytosis in vivo 
was similar using either PKH67-labeled ACs or ACs labeled with 
the pH-sensitive dye Cypher-5E (Figure 1E), which fluoresces only 
after entering the acidic late endosomes or lysosomes.
Application of this assay to mice with absent or inhibited candi-
date receptors revealed that deficiency of CD36, CD11b, or MERTK 
did not affect efferocytosis by CD8α+ splenic DCs (Figure 2A). 
A previous study using BMDCs from AXL/TYRO3 double-KO 
mice demonstrated a role for one or both of these receptors in 
DC efferocytosis in vitro (11). Here, we found that not only Axl–/–
Tyro3–/– mice, but also Axl–/– mice, were defective in DC efferocy-
tosis in vivo (Figure 2A), establishing that AXL is a physiologically 
important DC efferocytosis receptor.
We next explored LRP-1, which has previously been implicated 
in efferocytosis by macrophages, but not DCs (18, 19). Inhibition 
of LRP-1 by i.v. injection of GST-conjugated receptor-associated 
protein (GST-RAP), which binds LRP-1 and inhibits interaction 
of the receptor with a number of LRP-1 ligands (Supplemen-
tal Figure 1A; supplemental material available online with this 
article; doi:10.1172/JCI72051DS1; and ref. 20), inhibited splenic 
DC efferocytosis by approximately 50% (Figure 2A). To confirm 
the involvement of LRP-1 in DC efferocytosis, we generated 
Cd11cCre+Lrp1fl/fl mice, which have undetectable LRP-1 in splenic 
Figure 2
Screening for DC efferocytosis receptors in vivo. (A) In vivo splenic DC efferocytosis assay conducted 3 hours after injection of ACs in control 
mice and mice with absent or inhibited candidate efferocytosis receptors (n = 3 per group). The y axis represents the proportion of ACs engulfed 
by splenic CD8α+ DCs. LRP-1 was inhibited by i.v. injection of GST-RAP (2 mg/mouse), and TIM-3 was inhibited by i.p. injection of an anti–TIM-3 
nAb (RMT3-23; 100 μg/mouse). (B and C) Flow cytometric quantification of the percentage of total DCs (CD11chi) and CD8α+ DCs in the spleens 
of the indicated mice (n = 3 per group). (D–F) Flow cytometric analysis of expression of AXL (D), LRP-1 (E), and TIM-3 (F) in CD8α+ and CD8α– 
splenic DCs of WT mice. *P < 0.05 vs. respective control.
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DCs but intact expression in splenic macrophages (Supplemental 
Figure 1B). CD8α+ splenic DCs in these mice showed significantly 
decreased efferocytosis compared with control Lrp1fl/fl mice (Figure 
2A), further validating a role for LRP-1 in DC efferocytosis in vivo.
Further studies showed that CD8α+ DCs, which had greater 
efferocytic efficiency than CD8α– DCs (Figure 1C), expressed sub-
stantially higher levels of AXL and LRP-1 compared with CD8α– 
DCs (Figure 2, D and E); this was also the case for another DC 
efferocytosis molecule, TIM-3 (Figure 2F and see below). In this 
context, the decrease in efferocytosis observed in the Axl–/– and 
Cd11cCre+Lrp1fl/fl mice was not due to changes in the number of 
total or CD8α+ DCs (Figure 2, B and C) or in the efferocytosis effi-
ciency of splenic macrophages (Supplemental Figure 2). Further-
more, the spatial distribution of DCs within the splenic marginal 
zone, where most of the injected ACs traffic (21), was not different 
among WT, Axl–/–, and Cd11cCre+Lrp1fl/fl mice (data not shown).
We next explored 2 other molecules previously implicated in DC 
efferocytosis. Consistent with a previous report (10), injection of 
anti–TIM-3 neutralizing antibody (nAb) decreased efferocytosis 
by DCs in vivo (Figure 2A). An nAb against SCARF-1, another DC 
molecule recently shown to mediate the uptake of ACs (15), also 
inhibited efferocytosis by BMDCs in vitro in a manner that was 
additive to AXL and TIM-3 (Supplemental Figure 3A). Finally, we 
tested which molecules mediate efferocytosis by human splenic 
DCs and monocyte-derived DCs. Neutralization of AXL and LRP-1 
using anti-AXL antibody and GST-RAP, respectively, was associated 
with a significant reduction in human DC efferocytosis (Figure 3, A 
and B). The degree of inhibition was comparable to that obtained 
by neutralization of CD36 and αvβ3/β5, which were previously 
reported to facilitate efferocytosis by human DCs (7). Importantly, 
simultaneous blockage of all the receptors resulted in an additive 
effect on efferocytosis inhibition (Figure 3, A and B). However, 
blocking SCARF-1 using an nAb did not decrease efferocytosis by 
human splenic DCs, either singly or in combination with other 
efferocytosis receptor blocking antibodies (Figure 3B). To demon-
strate that the anti–SCARF-1 nAb was functional in human splenic 
DCs, we showed that it markedly decreased the uptake of one of 
SCARF-1’s ligands, acetylated LDL (Ac-LDL; Supplemental Figure 
3B). Interestingly, AXL and LRP-1 were highly expressed on human 
CD141+ splenic DCs (Figure 3C), which are orthologous to murine 
CD8α+ DCs in their efferocytosis and cross-presentation abilities 
(22, 23). Thus, similar to our observations with AXL/LRP-1 and 
TIM-3 in mice, human monocyte-derived DCs and splenic DCs 
used AXL/LRP-1, but not SCARF-1, in conjunction with other, 
parallel receptor pathways to carry out efferocytosis.
AXL and LRP-1 cooperate to mediate efferocytosis. In view of our find-
ing that the decreased DC efferocytosis in the spleens of Axl–/–, 
Cd11cCre+Lrp1fl/fl, and TIM-3–neutralized mice was only partial, we 
next sought to determine whether DC efferocytosis can be blocked 
further by various combinations of receptor inhibition. When 
Axl–/– mice were treated with an anti–TIM-3 nAb, the inhibition of 
splenic DC efferocytosis was additive (Figure 4A). This was not the 
case for CD36 or αV integrins (Supplemental Figure 4A), further 
supporting the data in Figure 2A suggesting these molecules are 
not involved in efferocytosis by murine DCs. Importantly, treat-
ment of Axl–/– mice with the LRP-1 inhibitor GST-RAP did not 
result in any additional decrease in efferocytosis compared with 
each manipulation alone (Figure 4B), which suggests that LRP-1 
and AXL function in the same pathway. In this context, it is impor-
tant to note that expression levels of LRP-1 in Axl–/– DCs and AXL 
in LRP-1–deficient DCs were comparable to those in WT DCs 
(Supplemental Figure 4B).
Figure 3
Human monocyte-derived DCs and 
splenic DCs utilize AXL and LRP-1 
for efferocytosis. (A and B) Human 
monocyte-derived DCs (MoDCs; 
n = 5; A) and splenic DCs (n = 7; B) 
were incubated with IgG control or 
the indicated combinations of nAbs 
against AXL, CD36, αV, or SCARF-1 
(0.5 μg/ml) (R&D Systems) or the 
LRP-1 blocker GST-RAP (1 μg/ml). 
Cells were then exposed to PKH67-
labeled apoptotic Jurkat cells (1:4 
ratio) for 2 hours and assayed 
for efferocytosis by microscopic 
analysis. (C) Representative flow 
cytometric analysis of expression 
levels of AXL and LRP-1 in human 
CD141– and CD141+ splenic DCs 
(n = 5). *P < 0.05 vs. respective con-
trol; #P < 0.05 vs. all other groups 
(except as indicated).
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To further explore the concept that AXL and LRP-1 might func-
tion in the same pathway, we considered the possibility that LRP-1 
and AXL might carry out different steps in efferocytosis, such 
as AC recognition versus engulfment (24). To assess the role of 
AXL and LRP-1 in AC binding, we used the actin polymerization 
inhibitor cytochalasin D to prevent AC internalization. Whereas 
Axl–/– DCs were clearly deficient in AC binding using this assay, 
inhibiting LRP-1 using GST-RAP did not affect this process (Fig-
ure 4C). In contrast, when the assay was carried out in the absence 
of cytochalasin D to enable engulfment, both AXL deficiency 
and GST-RAP were inhibitory (Figure 4D). Similar results were 
obtained when the binding experiment was conducted at 4°C to 
block internalization (data not shown). Notably, blocking LRP-1 
in Axl–/– BMDCs did not further augment the defect in AC engulf-
ment (Figure 4D), consistent with the in vivo data in Figure 4B. 
These findings suggest a model in which AXL is involved primarily 
in AC recognition by DCs, whereas LRP-1 functions in engulfment 
of the bound ACs, but not AC binding per se.
RANBP9 facilitates the functional interaction of AXL and LRP-1 in 
efferocytosis. We reasoned that if AXL and LRP-1 functioned in a 
binding-internalization cooperative manner, they might be in 
close proximity or even physically interact with each other. To test 
this hypothesis, we first conducted double immunofluorescence 
confocal microscopy on BMDCs. Within the resolution of this 
technique, the images were suggestive of AXL/LRP-1 colocaliza-
tion on the cell surface (Figure 5A). We also found that LRP-1 was 
expressed at a higher level than AXL in DCs (data not shown), 
which likely explains our finding that percent colocalization of 
AXL with LRP-1 was higher than that of LRP-1 with AXL (78% 
vs. 41%). To test our hypothesis using a complementary method, 
we determined whether AXL and LRP-1 could be coimmunopre-
cipitated in BMDCs. co-IP experiments showed the presence of 
LRP-1 in AXL IPs and the presence of AXL in LRP-1 IPs (Figure 
5B). Notably, AXL was not detected in the IPs of LRP-1 in Axl–/– 
DCs (Supplemental Figure 5A), confirming the specificity of the 
antibodies used in these experiments. To determine whether AXL 
and LRP-1 interact in splenic DCs in vivo, we conducted a fluo-
rescence resonance energy transfer (FRET) experiment in which 
primary antibodies recognizing AXL and LRP-1 were conjugated 
to Alexa Fluor 546 or Alexa Fluor 647 to act as FRET donor and 
acceptor, respectively. This assay was based on the principle that 
photons emitted by donor fluorophore can excite acceptor fluoro-
phore when they are within 100Å of each other. A positive FRET is 
indicated by both an increase in fluorescence of the acceptor (sen-
sitized emission) and a concomitant decrease in fluorescence of the 
donor (donor fluorescence quenching). FACS analysis of splenic 
DCs showed substantial FRET, as measured by analysis of both 
sensitized emission and donor fluorescence quenching (Figure 5, 
C and D). Moreover, consistent with our confocal data demonstrat-
ing greater colocalization of AXL with LRP-1, donor fluorescence 
quenching was greater when antibody against AXL was used as a 
donor (Figure 5D). As a control for this experiment, we showed that 
FRET was not observed in Axl–/– and LRP-1–deficient splenic DCs 
(Supplemental Figure 5B), thereby validating the fluorophore-con-
jugated antibodies used in this assay. In addition, FRET between 
fluorophore-conjugated antibodies against heavy and light chains 
of MHC class I, which are known to interact on the cell surface, was 
used as a positive control (Supplemental Figure 5C).
In order to determine the functional significance of AXL/LRP-1 
interaction, it was necessary to identify the mechanism respon-
sible for their association. Protein interaction algorithms sug-
gested that LRP-1 and AXL do not directly bind each other, so 
we hypothesized the presence of a scaffolding protein. Further 
database searching indicated that the protein RANBP9 interacts 
with AXL in cancer cells (25) and with LRP-1 in neuronal cells 
(26). Although RANBP9 has not previously been implicated in any 
functional interaction between AXL and LRP-1 or in efferocytosis, 
we considered the hypothesis that it can act as an AXL/LRP-1 scaf-
folding protein in DCs to couple AXL-mediated AC binding with 
LRP-1–mediated AC internalization.
We first probed the LRP-1 and AXL IPs for RANBP9 and found 
a positive immunoblot signal in both cases (Figure 5B), consistent 
with our scaffolding hypothesis. To test the functional signifi-
cance of this interaction, we created bone marrow chimeric mice 
using Ranbp9–/– donor cells, because Ranbp9–/– mice die in the early 
postnatal period (27). Thus, fetal liver cells from E15 Ranbp9–/– and 
WT embryos were transplanted into lethally irradiated C57BL/6J 
mice to generate chimeric mice in which BMDCs were deficient 
in RANBP9. As confirmation, we verified that splenic DCs in the 
Figure 4
AXL and LRP-1 cooperate to facilitate DC efferocytosis. (A and B) 
In vivo splenic DC efferocytosis was assayed in the indicated mice 
(n = 3 per group) 3 hours after injection of PKH67-labeled ACs. TIM-3 
nAb (100 μg) was administered i.p., and GST-RAP (2 mg/mouse) was 
administered i.v., 30 minutes before AC injection. (C) BMDCs derived 
from WT or Axl–/– mice were treated with 5 μg/ml cytochalasin D to 
block AC internalization. To measure AC binding, cells were incubated 
with fluorescently labeled ACs for 1 hour in the absence or presence of 
1 μg/ml GST-RAP to block LRP-1. (D) Similar to C, except the experi-
ment was conducted in the absence of cytochalasin D to measure AC 
engulfment. n = 3 independent experiments. *P < 0.05 vs. respective 
control; #P < 0.05 vs. all other groups.
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chimeric mice lost expression of RANBP9 compared with WT 
DCs (Supplemental Figure 6A). However, neither the expression 
level of AXL and LRP-1 in DCs nor the total number of CD8α+ 
DCs was affected by RANBP9 deficiency (Supplemental Figure 6, 
B–D). Consistent with our hypothesis, RANBP9 deficiency in DCs 
(assessed using BMDCs from Ranbp9fl/fl mice transduced with ade-
no-Cre) resulted in loss of FRET signal between AXL and LRP-1 
(Figure 6A). Moreover, AXL failed to coimmunoprecipitate with 
LRP-1 in Ranbp9–/– DCs (Figure 6B). These data demonstrated 
that RANBP9 deficiency disrupted AXL/LRP-1 interaction. Most 
importantly, efferocytosis by splenic DCs was defective in Ranbp9–/– 
chimeric mice (Figure 6C), but efferocytosis by splenic macro-
phages was unaffected (Supplemental Figure 6E). Furthermore, 
consistent with the concept that AXL functions to bind ACs, while 
AXL/LRP-1 interaction is necessary for subsequent engulfment, 
BMDCs from Ranbp9–/– chimeric mice showed normal AC binding, 
but defective AC engulfment (Figure 6D).
AC internalization after recognition by specific efferocytosis 
receptors involves actin cytoskeletal reorganization mediated by 
the GTP-bound form of Rac1 (28). Previous reports indicated 
that LRP-1 mediates AC engulfment through its adapter pro-
tein, engulfment adaptor PTB domain containing 1 (GULP1) 
(29), which facilitates the formation of Rac-GTP (30). Consistent 
with our hypothesis that LRP-1/GULP1 is primarily involved in 
engulfment of AXL-bound ACs, silencing GULP1 using siRNA in 
WT BMDCs (knockdown efficiency, >80%; data not shown) led 
to a significant decrease in AC engulfment, but AC binding was 
unaffected (Figure 6E). Furthermore, silencing GULP1 in Axl–/– 
BMDCs did not result in an additional decrease in AC engulf-
ment compared with Axl–/– BMDCs transfected with negative 
control scrambled RNA (Supplemental Figure 7), which suggests 
that LRP-1/GULP1 by itself is unable to mediate AC recognition 
and internalization. These data support the concept that AXL 
and LRP-1/GULP1 function as a complex in which AXL binds 
Figure 5
AXL and LRP-1 interact in DCs in vitro and in vivo. (A) Representative immunofluorescent confocal microscopy of BMDCs stained at 4°C with 
anti–LRP-1 antibody followed by Alexa Fluor 488–labeled secondary antibody (green), and with anti-AXL antibody followed by Alexa Fluor 568–
labeled secondary antibody (red). Points of AXL and LRP-1 colocalization are indicated by yellow staining in the merged image as well as in 
the mask of colocalization. Scale bar: 5 μm. (B) Endogenous AXL or LRP-1 was subjected to IP from whole-cell lysates of BMDCs, then probed 
by Western blotting for AXL, LRP-1, or RANBP9. Rabbit or rat IgG in the IP reaction was used as control. (C) Flow cytometric analysis of FRET 
(sensitized emission) in splenic DCs (CD11c+ gate) immunostained with fluorophore-conjugated antibody against AXL as donor and LRP-1 as 
acceptor (left) or vice versa (right). Other cells were stained singly with fluorophore-conjugated antibody against AXL (left) or LRP-1 (right) as 
donor. Cells stained with IgG conjugated to Alexa Fluor 546 were used as controls. (D) Donor fluorescence measurements in cells as in C. Data 
are representative of 3 independent experiments.
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ACs and LRP-1/GULP1 mediates AC engulfment through actin 
cytoskeletal rearrangement.
AXL- and LRP-1–deficient DCs do not have defects in macropinocyto-
sis and phagocytosis. As a test of specificity for the role of the AXL/
LRP-1/RANBP9 complex in DC efferocytosis, we next determined 
whether these molecules also play roles in the related processes 
of macropinocytosis, endocytosis, and phagocytosis. BMDCs 
obtained from WT, Axl–/–, and Cd11cCre+Lrp1fl/fl mice did not dem-
onstrate any difference in the uptake of FITC-labeled dextran, a 
measure of macropinocytosis (Figure 7A). There was also no dif-
ference in the uptake of DiI-labeled 
LDL, a measure of receptor-medi-
ated endocytosis (Figure 7B). Simi-
larly, there was no difference in the 
ability of these DCs to phagocytose 
fluorescently labeled 1-μm latex 
beads (Figure 7C). Thus, AXL- and 
LRP-1–deficient DCs have a specific 
defect in efferocytosis.
The AXL/LRP-1/RANBP9 effero-
cytosis receptor complex is critical for 
cross-presentation of AC-derived anti-
gens, both in vitro and in vivo. As men-
tioned above, one of the functional 
implications of DC efferocytosis 
is its ability to utilize AC-derived 
antigens for cross-presentation. 
We therefore tested whether ACs 
internalized via the AXL/LRP-1/
RANBP9 complex could provide 
antigens for cross-presentation. 
We first used an in vitro model in 
which DCs from WT, Axl–/–, or 
Cd11cCre+Lrp1fl/fl mice were incu-
bated with OVA-loaded ACs and 
then cocultured with CFSE-labeled 
CD8+ OT-I transgenic T cells. Both 
Axl–/– and Cd11cCre+Lrp1fl/fl DCs 
demonstrated decreased activation 
and proliferation of OT-I transgen-
ic T cells (Figure 8A), indicative of 
defective antigen cross-presentation 
in the mutant DCs. Importantly, 
the Axl–/– and Cd11cCre+Lrp1fl/fl DCs 
were not intrinsically defective at 
cross-presentation, since they were 
robust in cross-presenting soluble 
as well as bead-conjugated OVA 
(Figure 8, B and C).
The OVA assays were conducted 
in vitro using a model antigen, 
which is not directly relevant in vivo 
under physiologic or pathologic 
conditions. We therefore tested 
whether efferocytosis via the AXL/
LRP-1/RANBP9 complex has rele-
vance in antigen cross-presentation 
in a natural virus infection model. 
To achieve this, we used an experi-
mental model of systemic herpes 
simplex virus–1 (HSV-1) infection in mice, because clearance of 
HSV-1 in vivo is dependent on successful cross-presentation and 
elicitation of a protective CD8+ T cell response (31). To moni-
tor cross-presentation and activation of antigen-specific CD8+ 
T cells, we used mice that were adoptively transferred with CFSE-
labeled CD8+ T cells isolated from gBT-I.1 transgenic mice. These 
T cells are MHC class I–restricted, with antigen specificity to the 
immunodominant peptide from HSV glycoprotein B (gB498-
505) (32). Mice lacking AXL, LRP-1 in DCs (Cd11cCre+Lrp1fl/fl), 
or RANBP9 in BMDCs had a significant increase in the number 
Figure 6
Disruption of AXL/LRP-1 interaction by RANBP9 deficiency blocks DC efferocytosis. (A) FACS-FRET 
analysis showing sensitized emission and donor fluorescence quenching in BMDCs labeled with anti-
bodies against AXL conjugated to Alexa Fluor 546 as donor and against LRP-1 conjugated to Alexa Fluor 
647 as acceptor. BMDCs from Ranbp9fl/fl mice were transduced with adeno-Cre (purple line) to generate 
RANBP9-deficient DCs and with adeno-LacZ (red line) to serve as RANBP9-positive control DCs. Data 
for control DCs labeled singly with either Alexa Fluor 546–labeled anti-AXL antibody (green line) or Alexa 
Fluor 546–IgG (black line) are also shown. (B) IP of LRP-1 from whole-cell lysates of BMDCs derived 
from WT or Ranbp9–/– chimeric mice. AXL did not coimmunoprecipitate with LRP-1 in Ranbp9–/– DCs. 
(C) In vivo splenic DC efferocytosis assay in WT or Ranbp9–/– chimeric mice (n = 4 per group). (D) 
BMDCs obtained from WT or Ranbp9–/– chimeric mice were incubated with fluorescently labeled ACs 
at 4°C for 1 hour to quantify AC binding or at 37°C for 2 hours to quantify AC engulfment (n = 3 inde-
pendent experiments). (E) BMDCs transfected with siRNA against Gulp1 (siGULP #1 and #2, targeting 
different regions of the gene), or negative control scrambled RNA, were incubated with fluorescently 
labeled ACs at 4°C for 1 hour to quantify AC binding or at 37°C for 2 hours to quantify AC engulfment 
(n = 3 independent experiments). *P < 0.05 vs. respective control.
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of nonproliferating gB498-505–specific CD8+ T cells in HSV-1–
infected spleens (Figure 9A and Supplemental Figure 8A). Most 
importantly, in light of the role of CD8+ T cells in anti–HSV-1 
immunity, all 3 KO models showed enhanced virus-induced 
pathogenesis, as demonstrated by adrenomegaly (Supplemental 
Figure 8B), massive adrenal infiltration of monocytes and neutro-
phils (data not shown), and viral titers more than 3-fold higher 
than in control mice (Figure 9B). Moreover, the adrenal glands of 
the mutant mice showed a significant increase in the number of 
TUNEL+ cells (Figure 9C), consistent with both increased HSV-1–
induced apoptosis (33) and decreased efferocytic clearance of ACs. 
In theory, these data could be influenced by increased permissive-
ness of the KO cells to HSV-1 infection; however, HSV-1 infectivity 
was not increased in BMDCs lacking AXL or LRP-1 or in primary 
adrenal cells lacking AXL (Supplemental Figure 9). Furthermore, 
to directly relate these data to efferocytosis of HSV-1–killed cells, 
we rendered primary adrenal cells apoptotic by ex vivo infection 
with HSV-1 and then injected these ACs into WT and mutant 
mice. Consistent with the interpretation of the HSV-1 infection 
data, Axl–/– and Cd11cCre+Lrp1fl/fl mice demonstrated defective DC 
efferocytosis and decreased cross-presentation to gBT-I.1 CD8+ 
T cells (Supplemental Figure 10, A and B). Finally, to confirm and 
extend the biological significance of these findings, we compared 
the survival of WT and Cd11cCre+Lrp1fl/fl mice infected with a lethal 
dose of HSV-1 and found significantly decreased median survival 
in Cd11cCre+Lrp1fl/fl compared with WT mice (Cd11cCre+Lrp1fl/fl, 5.5 
days; WT, 8.5 days; Figure 9D). Thus, despite the presence of mul-
tiple DC efferocytosis receptors, the AXL/LRP-1/RANBP9 effero-
cytosis complex was functionally important in antigen acquisition 
for cross-presentation and elicitation of a protective CD8+ cyto-
toxic T cell response in the setting of a natural virus infection.
A recent in vitro study demonstrated that enveloped viruses uti-
lize DC TYRO3/AXL/MERTK (TAM) family receptors, including 
AXL, to promote viral replication via suppression of type I IFN 
responses (34). However, our in vivo data demonstrated that Axl–/– 
mice were more susceptible to HSV-1 (an enveloped virus) com-
pared with WT mice on days 4, 7, and 10 after infection (Figure 9B 
and Supplemental Figure 11A). Moreover, the levels of IFN-α in 
serum were not significantly different between WT and Axl–/– mice 
(Supplemental Figure 11B). These data raise the interesting pos-
sibility that the pathogen and host may compete for the same cel-
lular machinery. For example, during initial phases of infection, 
viruses may utilize TAM receptors on DCs to suppress an early 
IFN-α response and promote viral replication, while during later 
stages of infection, particularly when virus-induced ACs arise, 
DCs utilize the TAM receptor AXL to recognize ACs, including 
virus-infected ACs, triggering activation of CD8+ cytotoxic T cell 
response and clearance of virus.
Discussion
Efferocytosis by DCs serves several important functions, including 
maintenance of tolerance to self-antigens; initiation of immune 
response against virally infected cells; and, in theory, prevention of 
secondary necrosis of uncleared ACs (8). Numerous receptors have 
been implicated through in vitro and occasionally in vivo stud-
ies as being able to mediate AC uptake by a variety of phagocytic 
cell types (35). While these studies suggest that different types of 
phagocytes preferentially utilize specific sets of receptors to carry 
Figure 7
Macropinocytosis, receptor-mediated endocytosis, 
and phagocytosis are not altered in BMDCs lacking 
AXL or LRP-1. BMDCs from the indicated groups of 
mice were assayed for (A) macropinocytosis of FITC-
labeled dextran, (B) receptor-mediated endocytosis 
of DiI-labeled LDL, and (C) phagocytosis of 1-μm 
fluorescent beads (n = 3).
Figure 8
AXL- and LRP-1–deficient DCs show defective cross-
presentation of antigens only acquired by efferocyto-
sis. BMDCs from the indicated mice were pulsed with 
antigens by incubating with OVA-loaded apoptotic 
Jurkat cells (A), soluble OVA (B), or bead-conjugated 
OVA (C), then coincubated with CFSE-labeled CD8+ 
OT-I T cells for 72 hours. OT-I T cell proliferation was 
measured by flow cytometric analysis of CFSE dye 
dilution in CD8+-gated cells. Graphs are represen-
tative of 2 independent experiments. *P < 0.05 vs. 
respective control.
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out efferocytosis, there has been considerable uncertainty as to the 
receptors used by DCs for functionally important efferocytosis in 
vivo. The findings of the present study help clarify this critical 
area, with implications for understanding the roles of DC effero-
cytosis in physiology, pathophysiology, and possibly therapy, such 
as in DC-vaccine design (36).
AXL interacts with ACs through the bridging molecule GAS6, 
which binds both AXL and phosphatidylserine exposed on the 
surface of ACs (37). However, the mechanism by which AXL 
mediates AC engulfment was not previously elucidated. Here, 
we demonstrated that in murine DCs, AXL primarily acted as an 
AC recognition receptor that bound ACs, but did not internalize 
them. Engulfment of the bound ACs required RANBP9-mediated 
interaction of AXL with the LRP-1/GULP1 module. This mode 
of action raises the possibility of the tether-and-tickle hypoth-
esis proposed by Henson and colleagues, in which macrophages 
were shown to bind ACs through one of a number of receptors, 
but internalization required another molecule, referred to as 
PSR (24). In DCs, AXL is an AC tether, and it is possible that this 
process somehow “tickles” the LRP-1/GULP complex to mediate 
cytoskeletal rearrangement and AC internalization. However, fur-
ther studies will be needed to define if and how AC binding trig-
Figure 9
RANBP9, AXL, and LRP-1 play important roles in cross-presentation in an HSV-1 infection model. (A) Mice were infected i.v. with HSV-1 strain 
KOS (4 × 105 pfu/mouse). All mice also received 106 CFSE-labeled CD8+ T cells purified from spleens of gBT-I.1 transgenic mice. 4 days after 
infection, spleens of infected mice were analyzed for transgenic T cell proliferation by flow cytometric analysis of CFSE+CD8+ gated T cells. Data 
show percent undivided CFSE-labeled gBT-I.1 transgenic T cells. (B) HSV-1 titers in mouse adrenal glands 4 days after infection with HSV-1. 
(C) Representative microscopic images and quantification (n = 4 mice per group) of TUNEL staining in mouse adrenal glands 4 days after infec-
tion with HSV-1. Scale bars: 500 μm. (D) Kaplan-Meier survival curve analysis of WT Lrp1fl/fl mice and Cd11cCre+Lrp1fl/fl mice infected with a lethal 
dose of HSV-1 (2 × 108 pfu/mouse). Median survival of WT mice was 8.5 days, compared with 5.5 days for Cd11cCre+Lrp1fl/fl mice (P < 0.05; 
n = 10 per group). *P < 0.05 vs. respective control.
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Efferocytosis prevents secondary necrosis of ACs, and defects 
in efferocytosis have been linked to pathological tissue necrosis, 
such as that in the necrotic cores of advanced, clinically danger-
ous atherosclerotic lesions (47). For example, deletion of the 
macrophage efferocytosis receptors MERTK and LRP-1 have 
been demonstrated to exacerbate necrotic core formation in 
mouse models of advanced atherosclerosis (19, 48, 49). Interest-
ingly, observational studies have shown that the necrotic cores of 
clinically dangerous human atheromata are often surrounded by 
mature DCs, which are relatively inefficient efferocytes that can 
constitute up to 30% of the phagocyte population of atheroscle-
rotic lesions (7, 50, 51). Thus, pathologic accumulation of pools 
of efferocytosis-inefficient mature DCs may promote focal necro-
sis. However, testing of this hypothesis in atherosclerosis and in 
other pathological settings, such as in tumor immunosurveil-
lance, has been hampered by lack of knowledge of DC-specific 
efferocytosis receptors (2, 52). Here, we found that neither TIM-3 
neutralization nor RANBP9 deficiency blocked efferocytosis by 
macrophages in vivo (Figure 2 and Supplemental Figure 6E); 
thus, targeting these molecules may provide a strategy by which 
to interrogate the role of DC-specific efferocytosis in these set-
tings. Moreover, given the critical role of efferocytosis and antigen 
cross-presentation in suppressing autoimmune responses, future 
investigation of the role of the AXL/LRP-1/RANBP9 complex in 
this area is warranted.
In summary, we characterized a new multiprotein complex uti-
lized by DCs for efferocytosis and antigen cross-presentation in 
vivo and demonstrated a novel role for the scaffolding protein 
RANBP9 in facilitating DC efferocytosis. In addition to provid-
ing new insight and tools with which to study the physiologic 
and pathologic roles of DC efferocytosis, these findings may have 
implications for future DC-based immunotherapeutic strate-
gies. For example, proteins or peptides packaged in AC-mimetic 
nanoparticles targeted to the AXL/LRP-1/RANBP9 complex may 
enhance efficiency of antigen cross-presentation for the purpose 
of eliciting a desired immune response against cancer or patho-
gens or a tolerogenic response in the setting of autoimmunity.
Methods
Animals and animal maintenance. Cd11b–/– and OT-1 mice were obtained from 
Jackson Laboratories (stock nos. 003991 and 003831, respectively). Axl–/–
Tyro3–/–, Axl–/–, and Mertk–/– mice were generated as described previously 
(53, 54). Lrp1fl/fl mice (strain name B6;129S7-Lrp1tm2Her/J; JAX stock no. 
012604) were generated as described previously (55) and then bred with 
Cd11cCre+/+ mice (Jackson Laboratories; stock no. 008068) to generate 
Cd11cCre+Lrp1fl/fl mice. Ranbp9–/– embryos were harvested from pregnant 
mice obtained from Ranbp9+/– mating (27). Ranbp9fl/fl mice, with exon 3 
flanked by loxP sites, were generated using a targeting vector consisting of 
an FRT site–flanked β-neo cassette with loxP sites inserted upstream and 
downstream of exon 3 of the Ranbp9 gene. This construct was electropho-
resed into JM8A3 F1-derived ES cells. An ES cell clone (HEPD0592.3.D06) 
that had successfully undergone FLP-mediated recombination and no 
longer retained the cassette, but did retain the loxP-flanked exon 3, was 
obtained from The European Conditional Mouse Mutagenesis Program 
and injected in to C57BL/6 blastocysts. Male chimeric mice were then 
bred to C57BL/6J female mice for germline transmission. Male and female 
heterozygous Ranbp9fl/+ mice were bred with each other to generate homo-
zygous Ranbp9fl/fl mice, which were used as a source of BMDCs for this 
study. gBT-I.1 mice were provided by D. Carr (University of Oklahoma 
Health Sciences Center, Oklahoma City, Oklahoma, USA).
gers activation of the LRP-1/GULP complex, including whether 
RANBP9 simply keeps AXL and LRP-1 close enough to allow a 
direct tickle-type interaction between AXL and LRP-1 or whether 
RANBP9 plays a more complex role in the actual transmission of 
the putative tickle signal.
Several lines of in vitro evidence suggest that antigens derived 
from ACs via efferocytosis are cross-presented by DCs to activate 
antigen-specific CD8+ T cells (9, 38, 39). Antigen cross-presenta-
tion is an incompletely understood process that involves transfer 
of antigen-derived peptides into the cytosolic or vacuolar pathway 
for loading onto MHC class I (40). This process is influenced by a 
number of factors, including efficiency of antigen capture, nature 
of antigen, dose, expression levels of MHC class I, and antigen 
processing via proteolysis, which in turn can be regulated by the 
kinetics of endosomal maturation and acidification (40). Specifi-
cally, retention of the antigenic material in a less acidic early endo-
somal-like compartment appears to be critical for efficient antigen 
cross-presentation. Consistent with this idea, antigens targeted to 
different endocytosis receptors that vary in their kinetics of lyso-
somal targeting are cross-presented with different efficiencies (41). 
In this context, it is interesting to note that while CD36, αvβ5, and 
αvβ3 mediate uptake of ACs by human DCs in vitro, they do not 
play a significant role in antigen cross-presentation in vitro (12, 
13). Thus, the identification of efferocytosis receptors that are effi-
cient at targeting antigens for cross-presentation will likely have 
important implications for understanding basic DC biology and 
for therapeutically targeting antigens to optimally activate CD8+ 
T cells. Our present data showed that the AXL/LRP-1/RANBP9 
complex in DCs mediated cross-presentation of AC-derived anti-
gens both in vitro in an OVA–OT-I model as well as in vivo in a 
natural HSV-1 infection model. Consistent with a previous report, 
blocking TIM-3 using an anti–TIM-3 nAb resulted in inhibition of 
both efferocytosis and cross-presentation of AC-associated anti-
gen in vitro (data not shown). However, in view of the key roles of 
TIM-3 in T cell biology (14), addressing the role of TIM-3 in cross-
presentation in vivo will require the use of a DC-specific TIM-3 
deletion model, which has not yet been reported.
The transgenic OT-1 and gBT-I.1 CD8+ T cells featured in the 
present study are routinely used to assay antigen cross-presen-
tation on MHC class I (32, 42). While this is a useful system, it 
is highly sensitive; hence, the data derived from this assay must 
be interpreted in the context that the T cell subsets being moni-
tored in this model have receptors with single high-affinity anti-
gen specificity. In this context, it is remarkable that even par-
tial inhibition of efferocytosis via blockage of the AXL/LRP-1/
RANBP9 pathway resulted in inhibition of cross-presentation 
in this highly sensitive assay. It is likely that inhibition of cross-
presentation to endogenous T cells, which would presumably not 
express such high-affinity receptors, would be even higher than 
that observed with transgenic T cells. In support of this idea, our 
data demonstrated that blocking AXL/LRP-1/RANBP9–mediated 
efferocytosis resulted in enhanced HSV-1 pathogenesis, despite 
only approximately 30% inhibition in proliferation of gBT-I.1 
transgenic T cells. Whether additional or alternative mechanisms 
are involved in this effect will require further study. For example, 
DNGR-1, a c-type lectin receptor that recognizes F-actin exposed 
by necrotic cells (43, 44), has been implicated in mediating cross-
presentation and antiviral immunity by retaining the internalized 
necrotic cargo in an early endosomal compartment that facilitates 
cross-presentation (45, 46).
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trol was injected into mice 30 minutes prior to injection of labeled ACs. 
3 hours later, mice were euthanized by CO2 asphyxiation, and splenocytes 
were harvested by gently disaggregating the spleen tissue in a buffer con-
taining 300 μg/ml collagenase D (Sigma-Aldrich). The splenocytes were 
stained with fluorophore-conjugated antibodies against CD11c, CD8α, 
and F4/80 (BD Biosciences) and analyzed by flow cytometry (BD FACS 
calibur or BD FACS canto II) using FlowJo software (Tree Star Inc.). Cell 
sorting was conducted at the flow cytometry core facility of Columbia Cen-
ter for Translational Immunology using a BD influx cell sorter.
FRET assay. Antibodies against AXL and LRP-1 (R&D Systems and 
Sigma-Aldrich, respectively) were conjugated to Alexa Fluor 546 or Alexa 
Fluor 647 using a commercially available antibody labeling kit (Invitrogen). 
The labeling ratio was approximately 3, calculated according to the manu-
facturer’s instructions. Antibody labeling of cells was performed at 4°C for 
30 minutes. FRET analysis was conducted by flow cytometry on CD11chi-
gated cells using a BD FACS Calibur equipped with 488- and 635-nm 
lasers. Data were analyzed using FlowJo software.
IP and Western blotting. IP was performed by lysing in vitro–cultured DCs 
using an IP buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 
1 mM MgCl2, 1 mM CaCl2, 1% Triton X-100, and 1 tablet of Roche EDTA-
free protease inhibitor per 10 ml of buffer. Lysates were then incubated with 
protein A–sepharose beads (GE Healthcare) and 100 μg anti-AXL (Cell Sig-
naling Technology) or anti–LRP-1 (Sigma-Aldrich) antibody overnight at 
4°C on a rotor-shaker. Samples were centrifuged at 90 g for 5 minutes, and 
beads were washed and recentrifuged 3 times with IP buffer. Laemmli buffer 
was then added to the beads; after boiling, the suspensions were centrifuged 
at 9,000 g. The supernatant fractions were loaded onto 4%–20% Tris-glycine 
SDS-PAGE gels. After transfer onto nitrocellulose membranes, blots were 
probed for AXL (R&D Systems), LRP-1 (Sigma-Aldrich), and RANBP9 (Epi-
tomics) using specific antibodies, and the immunoreactive bands were visu-
alized by enhanced chemiluminescence (Thermo Scientific).
siRNA transfection. BMDCs (5 × 105 cells/well of 24-well non–tissue cul-
ture–treated plates) were resuspended in serum-free DMEM. siRNA trans-
fection complex was prepared by incubating 20 pmol Gulp1 siRNA (Qia-
gen) with Lipofectamine 2000 (Invitrogen) (1:1 ratio) in serum-free DMEM 
for 20 minutes at room temperature. BMDCs were incubated with 20 pmol 
siRNA transfection complex under serum-free conditions for 6 hours at 
37°C in a 5% CO2 incubator, after which the culture medium was supple-
mented with serum to a final concentration of 5%. Cells were harvested 
24 hours after transfection; knockdown efficiency was analyzed by measur-
ing Gulp1 mRNA by RT-qPCR.
Fetal liver transplantation. E15 embryos from pregnant mice of Ranbp9+/– 
matings were harvested. Portions of the tail and head were preserved for 
genotyping by PCR and Western blotting to identify Ranbp9–/– embryos. 
Under sterile conditions, the fetal livers were harvested, and cell suspen-
sions were prepared by passing the liver tissue sequentially 3 times through 
a 20-gauge needle and 1 time through a 25-gauge needle. Cells were cen-
trifuged at 130 g for 5 minutes, resuspended in serum-free DMEM, and 
counted using a hemocytometer. 2 × 106 cells were injected i.v. into lethally 
irradiated (10 Gy; Gammacell40 unit) C57BL/6J recipient mice. Recipient 
mice were fed antibiotic water (100 μg/ml neomycin and 10 μg/ml poly-
myxin B) for 2 weeks and then acidified water. Chimeric mice were used 
4 weeks after fetal liver transplantation.
In vitro antigen cross-presentation assay. Jurkat cells were incubated with 
1 mg/ml OVA, and the OVA-loaded cells were exposed to UV light to induce 
apoptosis. BMDCs from appropriate groups of mice were incubated with 
OVA-loaded ACs for 2 hours to facilitate efferocytosis. FACS-sorted CD8+ T 
cells from OT-1 transgenic mice, which express TCR specific to OVA257–264, 
were labeled with 5 μM CFSE as described previously (56). These CFSE-
labeled OT-1 T cells (5 × 104/well) were then cultured with BMDCs 
Primary culture of BMDCs. Murine bone marrow cells were isolated from 
the femurs of mice, cultured for 7 days in petri dishes in DMEM contain-
ing 10% FBS, and supplemented daily with GM-CSF (10 ng/ml) and IL-4 
(10 ng/ml). On day 3, half the medium was replaced to replenish nutrients. 
The nonadherent cells were harvested on day 7, and experiments were per-
formed by plating these cells on non–tissue culture–treated 24-well plates. 
To delete RANBP9 in BMDCs generated from the bone marrow of Ranbp9fl/fl 
mice, cells were transduced with an adenoviral vector encoding Cre or LacZ 
control at an MOI of 200:1 (virus/DC), and experiments were conducted 
48 hours later. Adeno-Cre and adeno-LacZ were obtained from Viraquest.
Generation of human peripheral blood monocyte-derived DCs. Buffy coats were 
obtained from New York Blood Center. The mononuclear cell layer was 
isolated by gradient centrifugation using Ficoll-Hypaque, then plated and 
incubated in tissue culture dishes. After 1 hour, the nonadherent cells were 
washed away. The medium (DMEM containing 10% FBS) was supplemented 
with 500 IU recombinant human GM-CSF and IL-4 on days 0 and 3 of 
culture. The nonadherent cell population on day 7 was used as DCs.
Human splenic DC isolation. Human spleen samples were maintained in 
cold saline and brought to the laboratory within 6 hours of organ procure-
ment. In order to ensure high live cell yield, samples were rapidly processed 
through both enzymatic and mechanical digestion methods. Spleen was 
cleaned of fat, chopped into small pieces, and placed into 50-ml conical 
tubes. Enzymatic digestion media (25 ml) was added (RPMI containing 
10% FBS, l-glutamate, sodium pyruvate, nonessential amino acids, penicil-
lin-streptomycin, 1 mg/ml collagenase D, 1 mg/ml trypsin inhibitor, and 
0.1 mg/ml DNase I) and incubated with mechanical shaking at 37°C for 
1 hour. Digested tissue was then disrupted using the gentleMACS tissue 
dissociator (Miltenyi Biotech), and the resulting suspension was passed 
through a stainless steel tissue sieve (mesh size, 10–150), followed by cen-
trifugation. Red blood cell lysis was performed by addition of 5 ml ACK 
lysis buffer (Cellgro) directly to the cell pellet and incubation with periodic 
agitation for 5 minutes. To remove dead cells and debris, cell pellets were 
resuspended in 20 ml of 30% percoll (GE Healthcare Life Sciences) and cen-
trifuged at 50 g for 12 minutes. The resulting top layer and bottom pellet 
were discarded. Cells were washed with complete RPMI to remove percoll, 
and the resulting cell suspension was passed through a 40-μm filter. DCs 
were obtained from this cell suspension by negative selection using human 
myeloid DC isolation kit (Miltenyi Biotech).
Generation of fluorescently labeled ACs. Mouse splenocytes (in vivo experi-
ments) or Jurkat cells (in vitro experiments) were labeled with PKH67-GL 
(2 μM; Sigma-Aldrich) per the manufacturer’s instructions. Cells were then 
exposed to ultraviolet light (254 nm, UVP) for 5 minutes for induction of 
apoptosis. After UV exposure, cells were incubated in a 37°C incubator 
with 5% CO2 for 1 hour (Jurkat cells) or 3 hours (splenocytes). We routinely 
obtained approximately 80% early ACs (annexin V+PI–) at these time points.
In vitro AC binding and engulfment assay. AC binding experiments were 
conducted on BMDCs (5 × 105 cells/well on 24-well non–tissue culture–
coated plates). Internalization was blocked either by pretreatment with 
5 μg/ml cytochalasin D for 30 minutes, followed by incubation with 
PKH67-labeled ACs (1:5 BMDC/AC ratio) for 1 hour at 37°C, or by incu-
bation with ACs at 4°C for 1 hour. AC engulfment experiments were con-
ducted by incubating DCs with ACs for 2 hours at 37°C in the absence 
of cytochalasin D. For quantification, cells were mounted on slides and 
analyzed by fluorescence microscopy to determine the percentage of DCs 
labeled with PKH67-tagged ACs.
In vivo splenic DC efferocytosis assay. 2 × 107 apoptotic splenocytes were 
labeled ex vivo with 100 μg/ml PKH67-GL or Cypher-5E (GE Healthcare) 
per the manufacturer’s instructions. The labeled cells were then injected i.v. 
into mice. For inhibition experiments, GST (2 mg/mouse i.v.), GST-RAP 
(2 mg/mouse i.v.), TIM-3 nAb (100 μg/mouse i.p.), or appropriate IgG con-
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Study approval. All animals used in this study were maintained in a bar-
rier facility. All animal protocols were approved by the Columbia Univer-
sity Institutional Animal Care and Use Committee. Human spleens were 
obtained from deceased organ donors, at the time of organ acquisition for 
transplantation, through an approved research protocol and MTA with 
the New York Organ Donor Network (NYODN). All donors were 73 years 
or younger, were free of chronic disease and cancer, and were negative for 
hepatitis B and C and for HIV. Because tissue samples were obtained from 
deceased individuals lacking identifiers for our experiments, this study did 
not qualify as human subjects research, as confirmed by the Columbia Uni-
versity Institutional Review Board. Research consent for the donor tissue 
was obtained by the NYODN transplant coordinators.
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exposed to OVA-loaded ACs (104/well) for 72 hours. Cells were stained 
with anti-CD8α (BD Biosciences) to specifically detect OT-1 T cells. CFSE 
dye dilution as a readout of T cell proliferation was analyzed by flow 
cytometry on CD8α+-gated cells.
HSV-1 culture, mouse infection, and virus titering. HSV-1 strain KOS was 
purchased from ATCC and propagated by infecting Vero cells (ATCC) as 
described previously (57). Mouse infection was conducted by i.v. injection 
of 4 × 105 pfu/mouse (self-limiting dose) or 2 × 108 pfu/mouse (lethal dose) 
of HSV-1 in an ABSL2 facility. For experiments assaying antigen cross-
presentation, mice were also injected with 1 × 106 CFSE-labeled gBT-I.1 
transgenic CD8+ T cells. Antigen cross-presentation was analyzed by mea-
suring CFSE dye dilution on CD8+CFSE+-gated cells on a flow cytometer. 
To estimate the virus burden in tissues of infected mice, homogenized tis-
sue samples were sonicated, and the resultant supernatant fraction was 
used to conduct virus titer analysis. Briefly, supernatants at several dilu-
tions were added to confluent Vero cells grown in 25-cm2 tissue culture 
flasks and incubated for 2 hours. After washing away free virus, 7.5 μg/ml 
pooled human Ig (Sigma-Aldrich) was added to prevent reinfection via 
extracellular virus particles. The flasks were incubated at 37°C for 2 days, 
and then plaques were visualized by Giemsa staining and counted.
Primary adrenal cell culture and induction of apoptosis by HSV-1 infection. 
Primary adrenal cells were cultured as described previously (58). Briefly, 
mice were euthanized, and both adrenal glands were isolated, minced, and 
digested in HBSS containing 2 mg/ml collagenase I, 0.05 mg/ml DNase I, 
and 5 mg/ml bovine serum albumin. The isolated cells were cultured on 
tissue culture dishes in KO-DMEM (Invitrogen) supplemented with 15% 
KO serum replacement (Invitrogen) for 3 days. To induce adrenal cell 
apoptosis, cells were infected with HSV-1 strain KOS (MOI, 10 pfu/cell) for 
2 hours. Cells were further cultured for 24 hours (at which point annexin V 
labeling revealed >65% of cells to be apoptotic), then UV-irradiated to inac-
tivate the virus prior to injection in mice.
Statistics. All data are expressed as mean ± SEM. Analysis of statistical 
significance was performed using 2-tailed Student’s t test; a P value less 
than 0.05 was considered statistically significant.
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